Viral Vaccine Assay Services for Influenza, HIV, and Emerging Pathogens

Influenza Vaccine Hemagglutination Inhibition (HAI) Assay Services

Measure functional antibody responses with WHO-aligned influenza strains

The hemagglutination inhibition assay remains a cornerstone of influenza vaccine immunogenicity evaluation. Our HAI assays quantify functional antibodies that block viral hemagglutinin from binding red blood cells, providing established correlates of protection for seasonal and pandemic influenza programs.

We offer:

• Influenza A and B strains
• WHO-recommended seasonal strains
• Pandemic and avian influenza strains
• Testing in single, duplicate, or triplicate formats
• Monoclonal and purified antibody analysis
• Human and preclinical species serum analysis (e.g., mouse, ferret)
• Positive control sera in parallel
• Geometric mean titers and seroconversion analysis

Representative Influenza HAI Reference Strains

Our hemagglutination inhibition (HAI) assay services are supported by a broad panel of seasonal, historical, and pandemic influenza A and B reference strains. The list below represents commonly requested isolates for influenza vaccine immunogenicity testing. Additional WHO-recommended and emerging strains are available upon request.

These strains are suitable for evaluation of geometric mean titers, seroconversion rates, and functional antibody response in preclinical and clinical vaccine studies.

Influenza A (H1N1)

Influenza A (H3N2)

Influenza B – Yamagata Lineage

Influenza B – Victoria Lineage

Influenza B – Victoria Lineage

Avian Influenza – H5N1

Avian Influenza – H7N9

Need a Different Strain?

We routinely update our influenza panels to reflect current WHO recommendations and emerging variants. If your vaccine candidate requires a specific seasonal, pandemic, or avian strain, our team can source, manufacture, and qualify the appropriate virus to support your HAI immunogenicity studies.

Influenza Vaccine Microneutralization (MN) Assay Services

Quantify neutralizing antibody potency with cell-based viral inhibition assays

Our microneutralization assays evaluate the ability of vaccine-induced antibodies to inhibit viral infection in susceptible cell lines. This cell-based neutralization assay provides sensitive detection of functional antibody responses beyond HAI alone.

We deliver:

• MN50 and MN90 titers
• Neutralization curves
• Cytopathic effect monitoring
• Approximately 100 TCID50 challenge dose
• Reference sera benchmarking
• Seasonal and avian influenza panels

Representative Influenza Microneutralization (MN) Reference Strains

Our influenza microneutralization (MN) assay services are supported by a focused panel of seasonal influenza A and B strains commonly used in vaccine neutralizing antibody studies. The strains listed below represent frequently requested isolates for evaluating functional antibody-mediated viral inhibition in preclinical and clinical vaccine programs.

These strains support determination of MN50 and MN90 titers, neutralization curves, and cytopathic effect inhibition using standardized infectious doses.

Influenza A (H1N1)

Influenza A (H3N2)

Influenza B – Yamagata Lineage

Influenza B – Victoria Lineage

Expanding Beyond the Representative Panel

Neutralization responses can vary significantly by strain and lineage. If your influenza vaccine candidate requires additional WHO-recommended seasonal strains, pandemic H1N1 or H3N2 isolates, or emerging variants, our team can source, manufacture, and qualify the appropriate virus for MN assay support.

These assay platforms can also be adapted to support antiviral compound evaluation and viral inhibition studies, providing flexibility for programs that span both vaccine and therapeutic development.

Influenza Vaccine Neuraminidase Inhibition (NAI) ELLA Assay Services

Measure anti-neuraminidase immunity using Enzyme-Linked Lectin Assay (ELLA)

Neuraminidase inhibition assays provide critical insight into vaccine-induced protection beyond hemagglutinin. Using the ELLA platform, we quantify inhibition of neuraminidase enzymatic activity via fetuin substrate cleavage and optical density readouts. NAI assays can be performed using both wild-type and reassortant influenza viruses. For neuraminidase-focused evaluations, reassortant or antigenically mismatched viruses are often preferred to isolate NA-specific antibody responses and minimize hemagglutinin interference.

Our NAI ELLA capabilities include:

• NA activity quantification
• IC50 and IC90 determination
• Enzyme inhibition profiling
• Optical density measurement and curve analysis
• Seasonal and avian influenza strains
• Fluorometric or ELLA formats

Representative Neuraminidase Inhibition (NAI/ELLA) Reference Strains

Our neuraminidase inhibition (NAI) Enzyme-Linked Lectin Assay (ELLA) services are supported by a panel of seasonal and historical influenza A and B reference strains. The strains listed below represent commonly requested isolates for evaluating anti-neuraminidase antibody responses in influenza vaccine development programs.

These strains support measurement of neuraminidase inhibition titers, IC50 and IC90 calculations, and functional enzyme activity profiling in both preclinical and clinical vaccine studies.

Influenza A (H1N1)

Influenza A (H3N2)

Influenza B – Yamagata Lineage

Influenza B – Victoria Lineage

Looking for a Specific Neuraminidase Target?

Influenza vaccine strategies increasingly evaluate neuraminidase immunity alongside hemagglutinin responses. If your program requires a specific WHO-recommended strain, emerging variant, or custom neuraminidase panel, our team can source, manufacture, and qualify the appropriate virus to support your NAI ELLA studies.

HIV Vaccine Neutralization and Immunogenicity Assay Services

Functional immunity testing for complex HIV vaccine programs

HIV vaccine development demands precise, reproducible, and biologically relevant assays capable of evaluating both neutralizing and non-neutralizing immune responses. Our team supports preclinical and clinical HIV vaccine studies with validated platforms designed to measure viral infectivity, antibody potency, viral load, and Fc-mediated effector function.

We work with primary cells, established T-cell lines, and reporter systems to generate defensible data aligned with global HIV vaccine research standards.

Representative HIV Strain Panel

Our HIV-1 and HIV-2 panels include well-characterized laboratory and clinical isolates commonly used in neutralization and infectivity studies.

HIV-1

• SPM-10516 (BEI ARP-1413)
• 92/BR/003 (BEI ARP-1751)
• 92/US/660 (BEI ARP-1722)
• RU132 (BEI ARP-3509)
• RTMDR1 (BEI ARP-2529)
• NL43 (Recovered by reverse genetics)

HIV-2

• SPM-10518 (BEI ARP-1108)
• CBL-20 (BEI ARP-600)
• CDC310072 (ARP-3649)

Additional clade-specific and custom isolates available upon request.

HIV Vaccine Assay Platforms

What This Means for Your HIV Vaccine Program

Biologically relevant systems
We work with primary cells and permissive T-cell lines to reflect true viral infectivity and immune interactions.

Functional antibody assessment
From neutralization to Fc-effector function, we support evaluation of both protective and non-neutralizing immune mechanisms.

Quantitative viral load analysis
Sensitive qRT-PCR and digital droplet PCR (ddPCR) platforms enable precise viral quantification across development stages.

Scalable study design
Assay throughput is structured to expand as vaccine programs move from exploratory studies to larger clinical cohorts.

Need a Specific Clade or Custom Neutralization Panel?

If your HIV vaccine strategy targets a specific clade, recombinant construct, or Fc-effector pathway, our team can design a fit-for-purpose assay panel aligned with your development objectives. Complete the form below to connect directly with our HIV assay specialists.

Custom Viral Vaccine Assay Development and Validation Services

Built for vaccine programs that do not fit inside a standard assay box

Not every vaccine candidate aligns neatly with a predefined assay panel. Novel constructs, emerging variants, recombinant platforms, and shifting regulatory expectations demand tailored solutions.

Our scientists partner directly with vaccine developers to design, optimize, validate, and transfer custom viral vaccine assays aligned to your antigen design, mechanism of action, and development stage. Whether you are advancing a preclinical candidate or generating GCLP-compliant clinical immunogenicity data, we build assays that reflect real viral biology and real regulatory requirements.

We support assay strategy across:

• Neutralizing antibody evaluation
• Functional infectivity testing
• Viral quantification
• Potency and stability assessment
• Technology transfer and assay qualification

When needed, we integrate custom viral stock production, recombinant virus generation, and containment expertise to create a seamless workflow from strain to final data package.

Custom Viral Vaccine Assay Platforms

Supported Viruses Include

We support assay strategy across:

• SARS-CoV-2
• Seasonal and avian influenza strains
• RSV
• Dengue virus
• Herpes simplex virus (HSV)
• Epstein-Barr virus (EBV)
• Emerging and novel viral targets

If your vaccine program involves a specific WHO-recommended influenza strain, a recombinant construct, or a newly emerging variant, we can source, manufacture, and qualify the appropriate viral material to support your assay program.

What Sets Our Custom Assay Approach Apart

Integrated viral expertise
We combine assay development with in-house viral propagation, characterization, and containment capabilities, including BSL-2 and BSL-3 environments.

Fit-for-purpose design
Every assay is built around your construct, dosing strategy, and clinical endpoints. We do not retrofit your science into a generic template.

Regulatory-aligned workflows
From early feasibility studies to GCLP-compliant clinical sample testing, we design assays with submission-readiness in mind.

Collaborative execution
Our scientists work alongside your team to refine protocols, interpret data, and adjust strategy as your program evolves.

Let’s Design the Right Assay Strategy for Your Vaccine Candidate

If your viral vaccine program requires custom neutralization testing, infectivity assays, recombinant virus systems, or advanced viral quantification methods, we are ready to build a solution around your needs.

Complete the form below to connect directly with our virology team and discuss your assay development goals.